Trials / Unknown
UnknownNCT02742727
CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma
Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and effectiveness of CAR-pNK cell immunotherapy in patients with CD7 positive relapsed or refractory Leukemia and Lymphoma.
Conditions
- Acute Myeloid Leukemia
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
- T-cell Prolymphocytic Leukemia
- T-cell Large Granular Lymphocytic Leukemia
- Peripheral T-cell Lymphoma, NOS
- Angioimmunoblastic T-cell Lymphoma
- Extranodal NK/T-cell Lymphoma, Nasal Type
- Enteropathy-type Intestinal T-cell Lymphoma
- Hepatosplenic T-cell Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | anti-CD7 CAR-pNK cells | The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD7 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD7. |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2017-03-01
- Completion
- 2018-03-01
- First posted
- 2016-04-19
- Last updated
- 2016-12-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02742727. Inclusion in this directory is not an endorsement.